Anti-VEGF ophthalmic drugs are a class of drugs used for ophthalmic treatment. Their main function is to inhibit the activity of vascular endothelial growth factor.

The global Anti-VEGF Ophthalmic Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Anti-VEGF Ophthalmic Drug Industry Forecast” looks at past sales and reviews total world Anti-VEGF Ophthalmic Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Ophthalmic Drug sales for 2024 through 2030. With Anti-VEGF Ophthalmic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Ophthalmic Drug industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF Ophthalmic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Ophthalmic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Ophthalmic Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Ophthalmic Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Ophthalmic Drug.

United States market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-VEGF Ophthalmic Drug players cover Eyetech, Pfizer Inc, Roche, Novartis, Regeneron, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Ophthalmic Drug market by product type, application, key manufacturers and key regions and countries.

• Pegaptanib
• Ranibizumab
• Aflibercept
• Brolucizumab
• Faricimab

• Online Sales
• Hospital
• Clinic
• Retail Pharmacy
• Others

This report also splits the market by region:

• United States
• Canada
• Mexico
• Brazil

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Germany
• France
• UK
• Italy
• Russia

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Eyetech
• Pfizer Inc
• Roche
• Novartis
• Regeneron
• Bayer
• Regeneron Pharmaceuticals
• Genentech
• Samsung Bioepis
• Biogen
• Qilu Pharmaceutical
• Innovent Biologics
• Kanghong Pharmaceutical
• Taikang Biology

1. What is the 10-year outlook for the global Anti-VEGF Ophthalmic Drug market?
2. What factors are driving Anti-VEGF Ophthalmic Drug market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Anti-VEGF Ophthalmic Drug market opportunities vary by end market size?
5. How does Anti-VEGF Ophthalmic Drug break out by Type, by Application?